- Home
- ARCC vs NBIX Comparison
ARCC vs NBIX Comparison
Compare ARCC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCC
- NBIX
- Stock Information
- Founded
- ARCC 2004
- NBIX 1992
- Country
- ARCC United States
- NBIX United States
- Employees
- ARCC N/A
- NBIX N/A
- Industry
- ARCC Finance/Investors Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARCC Finance
- NBIX Health Care
- Exchange
- ARCC Nasdaq
- NBIX Nasdaq
- Market Cap
- ARCC 15.8B
- NBIX 14.4B
- IPO Year
- ARCC 2004
- NBIX 1996
- Fundamental
- Price
- ARCC $19.09
- NBIX $138.99
- Analyst Decision
- ARCC Buy
- NBIX Strong Buy
- Analyst Count
- ARCC 9
- NBIX 17
- Target Price
- ARCC $23.00
- NBIX $164.94
- AVG Volume (30 Days)
- ARCC 6.6M
- NBIX 887.9K
- Earning Date
- ARCC 10-28-2025
- NBIX 10-28-2025
- Dividend Yield
- ARCC 10.05%
- NBIX N/A
- EPS Growth
- ARCC N/A
- NBIX 2.97
- EPS
- ARCC 2.03
- NBIX 3.39
- Revenue
- ARCC $3,011,000,000.00
- NBIX $2,509,900,000.00
- Revenue This Year
- ARCC $3.21
- NBIX $20.79
- Revenue Next Year
- ARCC $5.02
- NBIX $14.73
- P/E Ratio
- ARCC $9.39
- NBIX $40.92
- Revenue Growth
- ARCC 6.85
- NBIX 18.42
- 52 Week Low
- ARCC $18.26
- NBIX $84.23
- 52 Week High
- ARCC $23.84
- NBIX $154.61
- Technical
- Relative Strength Index (RSI)
- ARCC 19.56
- NBIX 51.17
- Support Level
- ARCC $20.03
- NBIX $135.96
- Resistance Level
- ARCC $20.43
- NBIX $141.14
- Average True Range (ATR)
- ARCC 0.40
- NBIX 3.18
- MACD
- ARCC -0.10
- NBIX -0.86
- Stochastic Oscillator
- ARCC 3.67
- NBIX 28.28
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.